Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Genentech has announced that the U.S. Food and Drug Administration approved the supplemental Biologics License Application (sBLA) for the manufacturing of Avastin™ (bevacizumab) bulk drug substance at the company's facility in Vacaville, California.
Scientists have developed a new screening technique to help them look for genes that change patients' responses to cancer drugs and other medications.
Erbitux (cetuximab), offers another option for patients who have colorectal cancer that resists standard chemotherapy treatment, according to an article written by two Mayo Clinic cancer researchers published in the current edition of the New England Journal of Medicine.
Cancer treatments, including the most commonly used chemotherapy agents as well as the newest biologic and targeted therapy drugs, can harm a patient’s heart, sometimes fatally
According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.
A drug designed to cut off a tumor’s blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.
A drug designed to cut off a tumor's blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.
Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.